Skip to main content
. Author manuscript; available in PMC: 2018 Jun 12.
Published in final edited form as: Mol Pharm. 2016 Nov 7;14(5):1365–1372. doi: 10.1021/acs.molpharmaceut.6b00929

Table 1. Plasma Pharmacokinetic Parameters of Gemcitabine (GEM) and Its Inactive Metabolite 2′,2′-Difluorodeoxyuridine (dFdU) after Single Intravenous Injection of Free GEM and mPEG-b-PCC-g-GEM-g-DC (Abbreviated as F-GEM and P-GEM) at GEM Equivalent Dose of 40 mg/kg in NSG Mice Bearing Orthotopic Pancreatic Tumors.

samples t1/2 (h) Cmax (ng/mL) Tmax (h) AUC (ng/mL × h) MRT (h)
F-GEM 1.99 ± 0.09 62923 ± 3479 0.25 83591 ± 1844 1.12 ± 0.13
P-GEM 5.77 ± 0.49 57462 ± 2403 0.25 246425 ± 1605 4.45 ± 0.15
dFdU from F-GEM 5.9 ± 2.02 19988 ± 1223 0.5 77555 ± 3570 6.58 ± 1.31
dFdU from P-GEM 10.03 ± 1.11 18287 ± 976 2 245708 ± 16552 14.93 ± 2.09